Fecal Microbiota Transplantation
From C. diff rescue to the frontier of microbiome medicine.
What's covered
- 01FMT for recurrent C. difficile infection: the evidence
- 02FDA-approved products: Rebyota (RBX2660), Vowst (SER-109)
- 03Donor screening and safety concerns
- 04FMT for IBD: current evidence and ongoing trials
- 05FMT for cancer immunotherapy modulation
- 06Defined microbial consortia: replacing whole stool with designed communities
- 07Regulatory landscape and commercialization
By the end of this module you will be able to
- L01Describe the evidence supporting FMT for recurrent C. difficile infection.
- L02Name the FDA-approved microbiome-based products and their indications.
- L03Evaluate the safety concerns and donor screening requirements for FMT.
- L04Discuss the evidence for FMT in IBD and immunotherapy modulation.
What you should walk away believing
- →FMT for rCDI is one of the most successful microbiome interventions: >85% cure rate.
- →Two FDA-approved products now exist — marking the transition from artisanal to regulated.
- →FMT for IBD is promising but heterogeneous; pooled donor, anaerobic preparation, and intensive dosing improve outcomes.
- →Defined consortia (e.g., SER-109) represent the future — standardized, scalable, safer.
What this means for you
Fecal transplant (FMT) involves transferring stool from a healthy donor to restore a patient's gut microbiome. It works remarkably well for recurring C. diff infections — curing over 85% of cases. The FDA has now approved two products based on this approach. Researchers are testing it for other conditions like IBD and to boost cancer treatment response, but that evidence is still early.
FMT for rCDI: multiple RCTs (van Nood 2013, PUNCH CD3, ECOSPOR III) demonstrate >85% cure rate; superior to vancomycin alone. FDA-approved: Rebyota (rectal, live biotherapeutic, 2022) and Vowst/SER-109 (oral capsules, spore-based, 2023). For IBD, pooled RCTs in UC show higher remission with intensive, pooled-donor FMT (FOCUS trial: 27% vs 8% remission at 8 weeks); Crohn's data is sparser. Cancer immunotherapy: Phase I/II FMT trials in anti-PD-1 non-responders show signals (Davar 2021, Baruch 2021).
The field is transitioning from whole-stool FMT to defined consortia and live biotherapeutics. SER-109 (Firmicutes spores) demonstrated non-inferiority to FMT in rCDI with better standardization. Defined 8-strain consortia (VE303) are in Phase II for CDI prevention. For IBD, engraftment analysis shows that donor strain persistence predicts clinical response — raising the possibility of personalized donor matching. Safety: transmitted infections (MDR E. coli, norovirus) have been reported; universal donor screening and IND requirements reflect these risks.
DIY FMT from the internet
A 32-year-old with recurrent C. difficile (3rd episode) is frustrated with antibiotic retreatment. She found a YouTube tutorial on preparing home FMT using her husband's stool and an enema kit. She asks your opinion before trying it.
How would you discuss the real risks of unscreened FMT (transmitted MDR infections, deaths reported), the availability of FDA-approved alternatives, and appropriate referral pathways?
What the data says
Test yourself
Spaced review
Key terms & abbreviations
- Fecal microbiota transplantationFMT
- Transfer of processed stool from a healthy donor to a patient's GI tract to restore microbial community composition.
- Defined microbial consortium
- A standardized preparation of specific, characterized microbial strains — more reproducible than whole-stool FMT.
Optional deeper dive
- Duodenal infusion of donor feces for recurrent C. difficile — van Nood E et al., NEJM 2013↗